|
1
|
Zhang D, Yang R, Wang S and Dong Z:
Paclitaxel: New uses for an old drug. Drug Des Devel Ther.
8:279–284. 2014.PubMed/NCBI
|
|
2
|
Hirose A, Tajima H, Ohta T, Tsukada T,
Okamoto K, Nakanuma S, Sakai S, Kinoshita J, Makino I, Furukawa H,
et al: Low dose paclitaxel inhibits the induction of
epidermal-mesenchymal transition in the human cholangiocarcinoma
CCKS-1 cell line. Oncol Lett. 6:915–920. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
He Q, Li J, Yin W, Song Z, Zhang Z, Yi T,
Tang J, Wu D, Lu Y, Wang Z, et al: Low-dose paclitaxel enhances the
anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell
vaccine in mouse model of prostate cancer. Cancer Immunol
Immunother. 60:715–730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsukada T, Fushida S, Harada S, Terai S,
Yagi Y, Kinoshita J, Oyama K, Tajima H, Ninomiya I, Fujimura T and
Ohta T: Low-dose paclitaxel modulates tumour fibrosis in gastric
cancer. Int J Oncol. 42:1167–1174. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barbuti AM and Chen ZS: Paclitaxel through
the ages of anticancer therapy: Exploring its role in
chemoresistance and radiation therapy. Cancer (Basel). 7:2360–2371.
2015. View Article : Google Scholar
|
|
6
|
Bocci G, Di Paolo A and Danesi R: The
pharmacological bases of the antiangiogenic activity of paclitaxel.
Angiogenesis. 16:481–492. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tao WY, Liang XS, Liu Y, Wang CY and Pang
D: Decrease of let-7f in low-dose metronomic paclitaxel
chemotherapy contributed to upregulation of thrombospondin-1 in
breast cancer. Int J Biol Sci. 11:48–58. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Di Paolo A, Bocci G and Danesi R: The
preclinical bases of the rational combination of paclitaxel and
antiangiogenic drugs. Clin Cancer Drugs. 1:100–115. 2014.
View Article : Google Scholar
|
|
9
|
Meyer N and Penn LZ: Reflecting on 25
years with MYC. Nat Rev Cancer. 8:976–990. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pelengaris S, Khan M and Evan G: C-MYC:
More than just a matter of life and death. Nat Rev Cancer.
2:764–776. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen BJ, Wu YL, Tanaka Y and Zhang W:
Small molecules targeting c-Myc oncogene: Promising anti-cancer
therapeutics. Int J Biol Sci. 10:1084–1096. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang X, Zhao X, Fiskus W, Lin J, Lwin T,
Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, et al: Coordinated
silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic
target of histone modification in aggressive B-cell lymphomas.
Cancer Cell. 22:506–523. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Douaiher J, Ravipati A, Grama B, Chowdhury
S, Alatise O and Are C: Colorectal cancer-global burden, trends,
and geographical variations. J Surg Oncol. 115:619–630. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goel A and Boland CR: Epigenetics of
colorectal cancer. Gastroenterology. 143:1442–1460. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li JP, Yang YX, Liu QL, Pan ST, He ZX,
Zhang X, Yang T, Chen XW, Wang D, Qiu JX and Zhou SF: The
investigational Aurora kinase A inhibitor alisertib (MLN8237)
induces cell cycle G2/M arrest, apoptosis, and autophagy via p38
MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Drug Des Devel Ther. 9:1627–1652. 2015.PubMed/NCBI
|
|
17
|
Bottone MG, Soldani C, Tognon G, Gorrini
C, Lazzè MC, Brison O, Ciomei M, Pellicciari C and Scovassi AI:
Multiple effects of paclitaxel are modulated by a high c-myc
amplification level. Exp Cell Res. 290:49–59. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sanders JA and Gruppuso PA: Nucleolar
localization of hepatic c-Myc: A potential mechanism for c-Myc
regulation. Biochim Biophys Acta. 1743:141–150. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie S, Ogden A, Aneja R and Zhou J:
Microtubule-binding proteins as promising biomarkers of Paclitaxel
sensitivity in cancer chemotherapy. Med Res Rev. 36:300–312. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Flatters SJ, Xiao WH and Bennett GJ:
Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful
peripheral neuropathy. Neurosci Lett. 397:219–223. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yun T, Liu Y, Gao D, Linghu E, Brock MV,
Yin D, Zhan Q, Herman JG and Guo M: Methylation of CHFR sensitizes
esophageal squamous cell cancer to docetaxel and paclitaxel. Genes
Cancer. 6:38–48. 2015.PubMed/NCBI
|
|
22
|
Wang S, Qiu J, Shi Z, Wang Y and Chen M:
Nanoscale drug delivery for taxanes based on the mechanism of
multidrug resistance of cancer. Biotechnol Adv. 33:224–241. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gatti G, Maresca G, Natoli M, Florenzano
F, Nicolin A, Felsani A and D'Agnano I: MYC prevents apoptosis and
enhances endoreduplication induced by paclitaxel. PLoS One.
4:e54422009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao HY, Ooyama A, Yamamoto M, Ikeda R,
Haraguchi M, Tabata S, Furukawa T, Che XF, Iwashita K, Oka T, et
al: Down regulation of c-Myc and induction of an angiogenesis
inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C
cells. Cancer Lett. 270:156–163. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liao Z, Nan G, Yan Z, Zeng L, Deng Y, Ye
J, Zhang Z, Qiao M, Li R, Denduluri S, et al: The anthelmintic drug
Niclosamide inhibits the proliferative activity of human
osteosarcoma cells by targeting multiple signal pathways. Curr
Cancer Drug Targets. 15:726–738. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wilmes A, Chan A, Rawson P, Jordan T
William and Miller JH: Paclitaxel effects on the proteome of HL-60
promyelocytic leukemic cells: Comparison to peloruside A. Invest
New Drugs. 30:121–129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
el Khyari S, Bourgarel V, Barra Y, Braguer
D and Briand C: Pretreatment by tubulin agents decreases C-MYC
induction in human colon carcinoma cell line HT29-D4. Biochem
Biophys Res Commun. 231:751–754. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fu Q, Chen Z, Gong X, Cai Y, Chen Y, Ma X,
Zhu R and Jin J: β-Catenin expression is regulated by an
IRES-dependent mechanism and stimulated by paclitaxel in human
ovarian cancer cells. Biochem Biophys Res Commun. 461:21–27. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Supino R, Favini E, Cuccuru G, Zunino F
and Scovassi AI: Effect of paclitaxel on intracellular localization
of c-Myc and P-c-Myc in prostate carcinoma cell lines. Ann N Y Acad
Sci. 1095:175–181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo
F, Lyssiotis CA, Aldape K, Cantley LC and Lu Z: ERK1/2-dependent
phosphorylation and nuclear translocation of PKM2 promotes the
Warburg effect. Nat Cell Biol. 14:1295–1304. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Supino R and Scovassi AI: c-myc: A
double-headed Janus that regulates cell survival and death. Gene
Ther Mol Biol. 8:385–394. 2004.
|
